

**A.M.GHELANI & COMPANY**  
**CHARTERED ACCOUNTANTS**

---

AJIT M. GHELANI  
B.Com.(Hons),F.C.A,GRAD.C.W.A.

CHINTAN A. GHELANI  
B.Com.(Hons),F.C.A,C.S.


**INDEPENDENT AUDITORS' REVIEW REPORT**

To,  
The Board of Directors  
Kilitch Drugs (India) Limited


**LIMITED REVIEW REPORT OF THE UNAUDITED STANDALONE RESULTS OF  
KILITCH DRUGS (INDIA) LIMITED FOR THE QUARTER/ SIX MONTHS ENDED  
30<sup>th</sup> SEPTEMBER, 2015**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Kilitch Drugs (India) Limited for the quarter/ six months ended 30th September, 2015, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the Accounting Standards issued under the Companies (Accounting Standards) Rules, 2006 which continue to apply as per Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rule, 2014 and other recognised accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement with the Stock Exchanges including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. M. Ghelani & Company  
Chartered Accountants  
(Firm Registration No. 103173W)

  
Chintan A. Ghelani  
Partner  
Membership No. 104391

Place: Mumbai  
Date: 11-11-2015



*Enclosed: Unaudited financial results for the quarter/ six months ended 30<sup>th</sup> September,  
2015 of Kilitch Drugs (India) Limited.*

**KILITCH DRUGS (INDIA) LIMITED****STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/SIX MONTHS ENDED  
30TH SEPTEMBER 2015**

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN. L24239MH1992PLC066718

Rs. In Lacs

PART I	Particulars	Three Months Ended			Six Months Ended		Year ended
		30-09-2015	30-06-2015	30-09-2014	30-09-2015	30-09-2014	31-03-2015
Sr. No.		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income from operations</b>						
	(a) Net Sales/income from operations(net of Excise)	428.73	395.74	604.48	824.47	1160.52	1843.73
	(b) Other operating income	2.31	3.67	16.49	5.98	31.15	59.00
	<b>Total income from Operations (Net)</b>	<b>431.05</b>	<b>399.41</b>	<b>620.97</b>	<b>830.46</b>	<b>1191.67</b>	<b>1902.73</b>
2	<b>Expenses</b>						
	(a) Cost of materials consumed	103.26	298.35	223.87	401.61	376.79	648.59
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	9.45	(13.24)	(71.04)	(3.79)	44.29	53.02
	(c) Employee Benefit Expenses	83.03	85.26	83.60	168.29	162.54	312.80
	(d) Depreciation and Amortisation Expenses	39.07	39.14	55.42	78.21	108.23	185.39
	(e) Export Product Registration Charges	30.90	14.65	24.24	45.55	72.16	110.13
	(f) Other Expenses	248.93	285.44	268.26	534.37	429.89	946.27
	<b>Total Expenses</b>	<b>514.63</b>	<b>709.60</b>	<b>584.35</b>	<b>1224.23</b>	<b>1193.90</b>	<b>2256.20</b>
3	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>(83.60)</b>	<b>(310.18)</b>	<b>36.62</b>	<b>(393.78)</b>	<b>(2.23)</b>	<b>(353.47)</b>
4	Other Income	17.84	57.62	61.05	75.46	127.24	269.02
5	<b>Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)</b>	<b>(65.75)</b>	<b>(252.56)</b>	<b>97.67</b>	<b>(318.31)</b>	<b>125.01</b>	<b>(84.45)</b>
6	Finance Costs	0.00	0.00	0.00	0.00	0.00	0.00
7	<b>Profit / (Loss) from ordinary activities before exceptional items (5-6)</b>	<b>(65.75)</b>	<b>(252.56)</b>	<b>97.67</b>	<b>(318.31)</b>	<b>125.01</b>	<b>(84.45)</b>
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9	<b>Profit / (Loss) from ordinary activities before tax (7+8)</b>	<b>(65.75)</b>	<b>(252.56)</b>	<b>97.67</b>	<b>(318.31)</b>	<b>125.01</b>	<b>(84.45)</b>
10	Tax Expenses						
	Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	Deferred Tax	(15.67)	(3.52)	(35.71)	(19.19)	(58.21)	(65.90)
	Tax Adjustments of Earlier years	0.00	0.00	0.00	0.00	0.00	0.00
11	<b>Net Profit / (Loss) from ordinary activities after tax (10+11)</b>	<b>(65.75)</b>	<b>(252.56)</b>	<b>97.67</b>	<b>(318.31)</b>	<b>125.01</b>	<b>(84.45)</b>
12	Extra Ordinary Items (net of tax expenses)	0.00	0.00	0.00	0.00	0.00	0.00
13	<b>Net Profit / (Loss) for the period (11+12)</b>	<b>(65.75)</b>	<b>(252.56)</b>	<b>97.67</b>	<b>(318.31)</b>	<b>125.01</b>	<b>(84.45)</b>
14	Paid-Up equity share capital (Face Value Rs 10 per share)	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18 10674.36
15	Reserve excluding Revaluation Reserve [As per the latest Audited Balance Sheet]						
16.i	Earnings per share (before extra ordinary items) (F.V. of Rs.10/-each) (not annualised):						
	(a) Basic	(0.38)	(1.88)	1.01	(2.26)	1.38	(0.14)
	(b) Diluted	(0.38)	(1.88)	1.01	(2.26)	1.38	(0.14)
16.ii	Earnings per share (after extra ordinary items) (F.V. of Rs.10/-each) (not annualised):						
	(a) Basic	(0.38)	(1.88)	1.01	(2.26)	1.38	(0.14)
	(b) Diluted	(0.38)	(1.88)	1.01	(2.26)	1.38	(0.14)



PART II OTHER INFORMATION FOR THE QUARTER/SIX MONTHS ENDED 30TH SEPTEMBER, 2015							
	Particulars	Three Months Ended			Six Months Ended		Year ended
		30-09-2015	30-06-2015	30-09-2014	30-09-2015	30-09-2014	31-03-2015
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>						
1	Public shareholding						
	a) Number of shares	4800955	4697655	4697655	4800955	4697655	4697655
	b) Percentage of shareholding	36.28	35.50	35.50	36.28	35.50	35.50
2	Promoters and Promoter Group Shareholding						
	a) Pledge / Encumbered						
	Number of shares	0.00	0.00	0.00	0.00	0.00	0.00
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)						
	Percentage of shares (as a % of the total share capital of the company)						
	b) Non- encumbered						
	Number of shares	8430873	8534173	8534173	8430873	8534173	8534173
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100	100	100
	Percentage of shares (as a % of the total share capital of the company)	63.72	64.50	64.50	63.72	64.50	64.50

B	INVESTOR COMPLAINTS	Quarter ended 30.09.2015
	Pending at the beginning of the Quarter	NIL
	Received during the quarter	4
	Disposed off during the quarter	4
	Remaining unresolved at the end of the quarter	NIL

**Notes:**

- The above results as reviewed by the audit committee have been taken on record by the Board of Directors at their meeting held on 11th November, 2015.
- During the quarter, the Company has formed a new subsidiary - Kilitch Estro Biotech, PLC, in the Republic of Ethiopia in which the Company has a holding of 97%.
- The Company has operated only in one reportable segment i.e. Pharmaceuticals.
- The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.

Place : Mumbai  
Date: 11th November, 2015



**KILITCH DRUGS (INDIA) LIMITED****STANDALONE STATEMENT OF ASSETS AND LIABILITIES**

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN. L24239MH1992PLC066718

Rs. (In Lacs)

Particulars	As at 30th Sep, 2015	As at 31st March, 2015
	[Rs.]	[Rs.]
	(Unaudited)	(Audited)
<b><u>EQUITY AND LIABILITIES</u></b>		
<b>Shareholders' Funds</b>		
Share capital	1,323.18	1,323.18
Reserves and surplus	10,375.24	10,674.37
<b>Non-Current Liabilities</b>		
<b>Current Liabilities</b>		
Trade payables	206.05	235.52
Other current liabilities	375.65	391.15
Short-term provisions	68.51	54.64
<b>TOTAL</b>	<b>12,348.63</b>	<b>12,678.86</b>
<b><u>ASSETS</u></b>		
<b>Non-Current Assets</b>		
<b>Fixed assets</b>		
Tangible assets	883.51	934.25
Intangible assets	3.76	4.11
Non-current investments	4,481.24	4,715.56
Deferred tax Assets (Net)	70.00	50.82
Long-term loans and advances	2,313.72	2,309.99
<b>Current Assets</b>		
Current investments	2,474.34	2,466.87
Inventories	294.99	238.12
Trade receivables	1,477.58	1,262.29
Cash and Bank balances	176.40	498.02
Short-term loans and advances	166.81	192.56
Other current assets	6.28	6.26
<b>TOTAL</b>	<b>12,348.63</b>	<b>12,678.86</b>

For and on Behalf of the Board

Place: Mumbai,

Dated: 11th November, 2015



MUKUND MEHTA  
(Managing Director)

